Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene

Clin Pharmacol Ther. 1986 Oct;40(4):400-7. doi: 10.1038/clpt.1986.197.


A chronic-dosing pharmacokinetic study was carried out in six healthy subjects to examine the potential for cimetidine to reduce the CLR and CLH of triamterene. Blood and urine samples were collected frequently for 24 hours after dosing with triamterene alone (100 mg/day) for 4 days and concomitant cimetidine (400 mg twice daily) for an additional 4 days. Cimetidine significantly reduced the clearance of triamterene by hydroxylation by 32% (P less than 0.016) and the CLR of triamterene by 28% (P less than 0.063), with no change in its protein binding. The CLR of the active sulfate conjugate of triamterene was not altered by cimetidine. There was a reduced recovery of triamterene and its metabolites in urine after cimetidine, suggesting a decreased absorption. These results are consistent with cimetidine inhibiting cytochrome P-450 enzymes in the liver and also competing with triamterene for renal tubular secretion. Despite the pharmacokinetic interaction, cimetidine caused minimal alteration to the natriuretic and antikaliuretic effects of triamterene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Cimetidine / pharmacology*
  • Drug Interactions
  • Humans
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kinetics
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Metabolic Clearance Rate
  • Triamterene / metabolism*


  • Cimetidine
  • Triamterene